LogicBio Therapeutics Financials
| LOGCDelisted Stock | USD 2.07 0.00 0.00% |
With this module, you can analyze LogicBio financials for your investing period. You should be able to track the changes in LogicBio Therapeutics individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
LogicBio |
Understanding current and past LogicBio Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of LogicBio Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in LogicBio Therapeutics' assets may result in an increase in income on the income statement.
The data published in LogicBio Therapeutics' official financial statements usually reflect LogicBio Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of LogicBio Therapeutics. For example, before you start analyzing numbers published by LogicBio accountants, it's critical to develop an understanding of what LogicBio Therapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of LogicBio Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, LogicBio Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in LogicBio Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of LogicBio Therapeutics. Please utilize our Beneish M Score to check the likelihood of LogicBio Therapeutics' management manipulating its earnings.
LogicBio Therapeutics Stock Summary
LogicBio Therapeutics competes with Lincoln Educational, Daily Journal, Hudson Pacific, Smith Douglas, and Addus HomeCare. LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts. Logicbio Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 62 people.| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US54142F1021 |
| Business Address | 65 Hayden Avenue |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | NYSE Composite |
| Website | www.logicbio.com |
| Phone | 617 245 0399 |
| Currency | USD - US Dollar |
You should never invest in LogicBio Therapeutics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of LogicBio Stock, because this is throwing your money away. Analyzing the key information contained in LogicBio Therapeutics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
LogicBio Therapeutics Key Financial Ratios
Generally speaking, LogicBio Therapeutics' financial ratios allow both analysts and investors to convert raw data from LogicBio Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of LogicBio Therapeutics over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that LogicBio Therapeutics reports annually and quarterly.LogicBio Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining LogicBio Therapeutics's current stock value. Our valuation model uses many indicators to compare LogicBio Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across LogicBio Therapeutics competition to find correlations between indicators driving LogicBio Therapeutics's intrinsic value. More Info.LogicBio Therapeutics is currently regarded as number one stock in return on equity category among related companies. It is currently regarded as number one stock in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value LogicBio Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for LogicBio Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the LogicBio Therapeutics' earnings, one of the primary drivers of an investment's value.LogicBio Therapeutics Market Pulse
| Quote | 2.07 |
| Change(%) | 0.00 |
| Change | 0.00 |
| Open | 2.07 |
| Low | 2.07 |
| High | 2.07 |
| Volume | 0 |
| Exchange | NASDAQ |
About LogicBio Therapeutics Financials
What exactly are LogicBio Therapeutics Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include LogicBio Therapeutics' income statement, its balance sheet, and the statement of cash flows. Potential LogicBio Therapeutics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although LogicBio Therapeutics investors may use each financial statement separately, they are all related. The changes in LogicBio Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on LogicBio Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Steps to analyze LogicBio Therapeutics Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as LogicBio Therapeutics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of LogicBio has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if LogicBio Therapeutics' financials are consistent with your investment objective using the following steps:- Review LogicBio Therapeutics' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand LogicBio Therapeutics' liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare LogicBio Therapeutics' financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if LogicBio Therapeutics' stock is overvalued or undervalued.
LogicBio Therapeutics April 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of LogicBio Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of LogicBio Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of LogicBio Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing LogicBio Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build LogicBio Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 4.26 | |||
| Information Ratio | 0.1144 | |||
| Maximum Drawdown | 644.93 | |||
| Value At Risk | (5.26) | |||
| Potential Upside | 5.56 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the LogicBio Therapeutics information on this page should be used as a complementary analysis to other LogicBio Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Consideration for investing in LogicBio Stock
If you are still planning to invest in LogicBio Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the LogicBio Therapeutics' history and understand the potential risks before investing.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Stocks Directory Find actively traded stocks across global markets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities |